Format

Send to

Choose Destination
Neurology. 1989 Dec;39(12):1635-7.

A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis.

Author information

1
Department de Pharmacologie Clinique Group, Hospitalier Pitié-Salpêtrière, Paris, France.

Abstract

We performed a 3-month, double-blind, placebo-controlled trial of 300 mg of gangliosides (Cronassial) in 40 outpatients with amyotrophic lateral sclerosis (ALS). We evaluated drug effect through physical examinations and symptom scales. Though this dosage had no major toxic effect, Cronassial treatment did not significantly benefit ALS patients.

PMID:
2685660
DOI:
10.1212/wnl.39.12.1635
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center